{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:29:04Z","timestamp":1790774944764,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T00:00:00Z","timestamp":1538956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s00066-018-1356-5","type":"journal-article","created":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T04:07:33Z","timestamp":1538971653000},"page":"1144-1151","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Long-term survival of patients after ipilimumab and hypofractionated brain radiotherapy for brain metastases of malignant melanoma: sequence matters","Langfristiges \u00dcberleben nach Ipilimumab und hypofraktionierter Ganzhirnbestrahlung bei Hirnmetastasen maligner Melanome: die Reihenfolge ist relevant"],"prefix":"10.1007","volume":"194","author":[{"given":"Heinz","family":"Schmidberger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Rapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Ebersberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silla","family":"Hey-Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Loquai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Grabbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3101-9180","authenticated-orcid":false,"given":"Arnulf","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,8]]},"reference":[{"issue":"14","key":"1356_CR1","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1200\/jco.2004.12.149","volume":"22","author":"JS Barnholtz-Sloan","year":"2004","unstructured":"Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan detroit cancer surveillance system. J\u00a0Clin Oncol 22(14):2865\u20132872. \n                    https:\/\/doi.org\/10.1200\/jco.2004.12.149","journal-title":"J Clin Oncol"},{"issue":"4","key":"1356_CR2","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1200\/jco.2007.12.7837","volume":"26","author":"EL Korn","year":"2008","unstructured":"Korn EL, Liu P\u2011Y, Lee SJ, Chapman J\u2011AW, Niedzwiecki D, Suman VJ, Moon J, Sondak VK, Atkins MB, Eisenhauer EA, Parulekar W, Markovic SN, Saxman S, Kirkwood JM (2008) Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J\u00a0Clin Oncol 26(4):527\u2013534. \n                    https:\/\/doi.org\/10.1200\/jco.2007.12.7837","journal-title":"J Clin Oncol"},{"issue":"1","key":"1356_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3171\/jns.1998.88.1.0011","volume":"88","author":"JH Sampson","year":"1998","unstructured":"Sampson JH, Carter JH, Friedman AH, Seigler HF (1998) Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J\u00a0Neurosurg 88(1):11\u201320. \n                    https:\/\/doi.org\/10.3171\/jns.1998.88.1.0011","journal-title":"J Neurosurg"},{"issue":"7","key":"1356_CR4","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1200\/jco.2004.08.140","volume":"22","author":"KM Fife","year":"2004","unstructured":"Fife KM, Colman MH, Stevens GN, Firth IC, Moon D, Shannon KF, Harman R, Petersen-Schaefer K, Zacest AC, Besser M, Milton GW, McCarthy WH, Thompson JF (2004) Determinants of outcome in melanoma patients with cerebral metastases. J\u00a0Clin Oncol 22(7):1293\u20131300. \n                    https:\/\/doi.org\/10.1200\/jco.2004.08.140","journal-title":"J Clin Oncol"},{"key":"1356_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-018-1287-1","author":"M R\u00fcckert","year":"2018","unstructured":"R\u00fcckert M, Deloch L, Fietkau R, Frey B, Hecht M, Gaipl US (2018) Immune modulatory effects of radiotherapy as basis for well-reasoned radioimmunotherapies. Strahlenther Onkol. \n                    https:\/\/doi.org\/10.1007\/s00066-018-1287-1","journal-title":"Strahlenther Onkol"},{"issue":"1","key":"1356_CR6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s00066-015-0923-2","volume":"192","author":"EG Troost","year":"2016","unstructured":"Troost EG (2016) Stereotactic radiotherapy augments the immune response. Strahlenther Onkol 192(1):70\u201371. \n                    https:\/\/doi.org\/10.1007\/s00066-015-0923-2","journal-title":"Strahlenther Onkol"},{"issue":"9","key":"1356_CR7","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s00066-017-1179-9","volume":"193","author":"R Baumann","year":"2017","unstructured":"Baumann R, Dunst J (2017) Radiotherapy enhances the effect of PD-1 checkpoint inhibitors. Strahlenther Onkol 193(9):763\u2013764. \n                    https:\/\/doi.org\/10.1007\/s00066-017-1179-9","journal-title":"Strahlenther Onkol"},{"issue":"4","key":"1356_CR8","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/s0360-3016(96)00619-0","volume":"37","author":"L Gaspar","year":"1997","unstructured":"Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R (1997) Recursive Partitioning Analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37(4):745\u2013751. \n                    https:\/\/doi.org\/10.1016\/s0360-3016(96)00619-0","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"13","key":"1356_CR9","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","volume":"16","author":"AB Sharabi","year":"2015","unstructured":"Sharabi AB, Lim M, DeWeese TL, Drake CG (2015) Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol 16(13):e498\u2013e509. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(15)00007-8","journal-title":"Lancet Oncol"},{"issue":"8","key":"1356_CR10","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/nejmoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJM, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebb\u00e9 C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N\u00a0Engl J Med 363(8):711\u2013723. \n                    https:\/\/doi.org\/10.1056\/nejmoa1003466","journal-title":"N Engl J Med"},{"issue":"26","key":"1356_CR11","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/nejmoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert C, Thomas L, Bondarenko I, O\u2019Day S, Weber J, Garbe C, Lebbe C, Baurain J\u2011F, Testori A, Grob J\u2011J, Davidson N, Richards J, Maio M, Hauschild A, Miller WH, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen T\u2011T, Humphrey R, Hoos A, Wolchok JD (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N\u00a0Engl J Med 364(26):2517\u20132526. \n                    https:\/\/doi.org\/10.1056\/nejmoa1104621","journal-title":"N Engl J Med"},{"issue":"5","key":"1356_CR12","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/s1470-2045(12)70090-6","volume":"13","author":"K Margolin","year":"2012","unstructured":"Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, Richards J, Michener T, Balogh A, Heller KN, Hodi FS (2012) Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13(5):459\u2013465. \n                    https:\/\/doi.org\/10.1016\/s1470-2045(12)70090-6","journal-title":"Lancet Oncol"},{"issue":"1","key":"1356_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2340\/00015555-1654","volume":"94","author":"MP Konstantinou","year":"2014","unstructured":"Konstantinou MP, Dutriaux C, Gaudy-Marqueste C, Mortier L, Bedane C, Girard C, Thellier S, Jouary T, Grob JJ, Richard MA, Templier C, Sakji L, Guillot B, Paul C, Meyer N (2014) Ipilimumab in melanoma patients with brain metastasis: a\u00a0retro-spective multicentre evaluation of thirty-eight patients. Acta Derm Venereol 94(1):45\u201349. \n                    https:\/\/doi.org\/10.2340\/00015555-1654","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"1356_CR14","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3171\/2012.5.jns111929","volume":"117","author":"JPS Knisely","year":"2012","unstructured":"Knisely JPS, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VLS (2012) Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J\u00a0Neurosurg 117(2):227\u2013233. \n                    https:\/\/doi.org\/10.3171\/2012.5.jns111929","journal-title":"J Neurosurg"},{"issue":"6","key":"1356_CR15","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/cam4.140","volume":"2","author":"AW Silk","year":"2013","unstructured":"Silk AW, Bassetti MF, West BT, Tsien CI, Lao CD (2013) Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med 2(6):899\u2013906. \n                    https:\/\/doi.org\/10.1002\/cam4.140","journal-title":"Cancer Med"},{"issue":"3","key":"1356_CR16","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/cmr.0b013e32835f3d90","volume":"23","author":"M Mathew","year":"2013","unstructured":"Mathew M, Tam M, Ott PA, Pavlick AC, Rush SC, Donahue BR, Golfinos JG, Parker EC, Huang PP, Narayana A (2013) Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res 23(3):191\u2013195. \n                    https:\/\/doi.org\/10.1097\/cmr.0b013e32835f3d90","journal-title":"Melanoma Res"},{"issue":"2","key":"1356_CR17","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.ijrobp.2015.01.004","volume":"92","author":"AP Kiess","year":"2015","unstructured":"Kiess AP, Wolchok JD, Barker CA, Postow MA, Tabar V, Huse JT, Chan TA, Yamada Y, Beal K (2015) Stereotactic radiosurgery for melanoma brain\u00a0metastases in patients receiving Ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys 92(2):368\u2013375. \n                    https:\/\/doi.org\/10.1016\/j.ijrobp.2015.01.004","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"1356_CR18","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1093\/neuonc\/nov093","volume":"17","author":"KR Patel","year":"2015","unstructured":"Patel KR, Lawson DH, Kudchadkar RR, Carthon BC, Oliver DE, Okwan-Duodu D, Ahmed R, Khan MK (2015) Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases. Neuro-Oncology 17(10):1312\u20131321. \n                    https:\/\/doi.org\/10.1093\/neuonc\/nov093","journal-title":"Neuro-Oncology"},{"issue":"9","key":"1356_CR19","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1001\/jamaoncol.2015.2756","volume":"1","author":"S Demaria","year":"2015","unstructured":"Demaria S, Golden EB, Formenti SC (2015) Role of local radiation therapy in cancer immunotherapy. JAMA Oncol 1(9):1325\u20131332. \n                    https:\/\/doi.org\/10.1001\/jamaoncol.2015.2756","journal-title":"JAMA Oncol"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00066-018-1356-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-018-1356-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-018-1356-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,7]],"date-time":"2019-10-07T19:20:11Z","timestamp":1570476011000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00066-018-1356-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,8]]},"references-count":19,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1356"],"URL":"https:\/\/doi.org\/10.1007\/s00066-018-1356-5","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,8]]},"assertion":[{"value":"20 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.\u00a0Schmidberger and A.\u00a0Mayer report grants from Varian Inc., outside the submitted work. C.\u00a0Loquai reports personal fees from Roche, Amgen, Novartis, Pierre Fabre, MSD, BMS, and Leo, outside the submitted work. S.\u00a0Grabbe reports personal fees from Bristol Myers Squibb, Merck, Novartis, and Roche, outside the submitted work. M.\u00a0Rapp, A.\u00a0Ebersberger and S.\u00a0Hey-Koch declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}